The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 3, 2009, Pages 258-262

  Gofrit, Ofer N ^a,b   Pode, Dov ^a   Pizov, Galina ^a   Zorn, Kevin C ^b   Katz, Ran ^a   Duvdevani, Mordechi ^a   Shapiro, Amos ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Bacillus Calmette G erin immunotherapy; Bladder carcinoma in situ; Prognosis

Indexed keywords

BCG VACCINE;

AGED; ARTICLE; BCG VACCINATION; BLADDER BIOPSY; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER MORTALITY; CARCINOMA IN SITU; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG INSTILLATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RECURRENT CANCER; SURVIVAL RATE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; BCG VACCINE; CARCINOMA IN SITU; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 65349120585     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.12.011     Document Type: Article

References (28)

1. Bostwick D.G., Ramnani D., and Cheng L. Diagnosis and grading of bladder cancer and associated lesions. Urol Clin North Am 26 (1999) 493-507
2. Sanchez-Fernandez de Sevilla M.C., Morell-Quadreny L., Gil-Salom M., et al. Morphometric and immunohistochemical characterization of bladder carcinoma in situ and its preneoplastic lesions. Eur Urol 21 1 (1992) 5-9
3. Brawn P.N. The origin of invasive carcinoma of the bladder. Cancer 50 (1982) 515-519
4. Lee R., and Droller M.J. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 27 (2000) 1-13
5. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331 (1994) 1259-1264
6. Skinner D.G., Richie J.P., Cooper P.H., et al. The clinical significance of carcinoma in situ of the bladder and its association with overt carcinoma. J Urol 112 (1974) 68-71
7. Koss L.G., Tiamson E.M., and Robbins M.A. Mapping cancerous and precancerous bladder changes. A study of the urothelium in ten surgically removed bladders. JAMA 227 (1974) 281-286
8. Althausen A.F., Prout Jr. G.R., and Daly J.J. Noninvasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 116 (1976) 575-580
9. Hudson M.A., and Herr H.W. Carcinoma in situ of the bladder. J Urol 153 (1995) 564-572
10. Lamm D.L., Blumenstein B.A., Crawford E.D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Gúerin for transitional-cell carcinoma of the bladder. N Engl J Med 325 (1991) 1205-1209
11. de Reijke T.M., Kurth K.H., Sylvester R.J., et al. Bacillus Calmette-Gúerin vs. epirubicin for primary, secondary, or concurrent carcinoma in situ of the bladder: Results of a European Organization for the Research and Treatment of Cancer, Genito-Urinary Group, Phase III trial (30906). J Urol 173 (2005) 405-409
12. Sylvester R.J., van der Meijden A.P., Witjes J.A., et al. Bacillus Calmette-Guérin vs. chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder. A meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005) 86-91
13. Herr H.W., Wartinger D.D., Fair W.R., et al. Bacillus Calmette-Gúerin therapy for superficial bladder cancer. A 10-year followup. J Urol 147 (1992) 1020-1023
14. Prout Jr. G.R., Griffin P.P., Daly J.J., et al. Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms. Cancer 52 (1983) 524-532
15. Orozco R.E., Martin A.A., and Murphy W.M. Carcinoma in situ of the urinary bladder. Clues to host involvement in human carcinogenesis. Cancer 74 (1994) 115-122
16. Cheng L., Cheville J.C., Neumann R.M., et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 85 (1999) 2469-2474
17. Jakse G., Hall R., Bono A., et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: Long-term results of EORTC GU Group Phase II protocol 30861. Eur Urol 40 (2001) 144-150
18. Herr H.W., Badalament R.A., Amato D.A., et al. Superficial bladder cancer treated with bacillus Calmette-Gúerin: A multivariate analysis of factors affecting tumor progression. J Urol 141 (1989) 22-29
19. Mostofi F.K., Sobin L.H., and Torloni H. International histological classification of tumors, No 10. Histological typing of urinary bladder tumors (1973), World Health Organization, Geneva
20. Haaff E.O., Dresner S.M., Ratliff T.L., et al. Two courses of intravesical bacillus Calmette-Gúerin for transitional cell carcinoma of the bladder. J Urol 136 (1986) 820-824
21. Malkowicz S.B., Nichols P., Lieskovsky G., et al. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS, and P2). J Urol 144 (1990) 641-645
22. Jenkins B.J., England H.R., Fowler C.G., et al. Chemotherapy for carcinoma in situ of the bladder. Br J Urol 61 (1988) 326-329
23. Kaasinen E., Wijkström H., Malmström P.U., et al. Alternating mitomycin C and BCG instillations vs. BCG alone in treatment of carcinoma in situ of the urinary bladder: A Nordic study. Eur Urol 43 (2003) 637-645
24. Merz V.W., Marth D., Kraft R., et al. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Gúerin for carcinoma in situ of the bladder. Br J Urol 75 (1995) 180-184
25. Pfister C., Moore L., Allard P., et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 5 (1999) 4079-4084
26. Inman B.A., Sebo T.J., Frigola X., et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: Associations with localized stage progression. Cancer 109 (2007) 1499-1505
27. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Gúerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
28. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Gúerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970